Market revenue in 2023 | USD 33.7 million |
Market revenue in 2030 | USD 65.3 million |
Growth rate | 9.9% (CAGR from 2023 to 2030) |
Largest segment | Epinephrine |
Fastest growing segment | Immunotherapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 47.48% in 2023. Horizon Databook has segmented the UK peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
In the UK, a significant development is occurring in the peanut allergy treatment market. The NHS England secured a deal for Palforzia, an oral treatment that reduces the severity of peanut allergy symptoms, including anaphylaxis. This treatment is set to make a difference in the lives of children across the country.
In its initial phase, Palforzia will be made available to a group of up to 600 children between the ages of 4 and 17. Following this, the availability of the treatment is expected to expand, reaching as many as 2,000 children in the subsequent year. This milestone marks a substantial step forward in addressing the challenges faced by families dealing with peanut allergies.
Most patients are dependent on adrenaline injections to counter the potential threat of anaphylaxis, a severe and potentially life-threatening allergic reaction. The development of Palforzia is the result of two substantial clinical trials, the Palisade and Artemis studies, in which the Evelina London Children's Hospital played an active role.
Horizon Databook provides a detailed overview of country-level data and insights on the UK peanut allergy treatment market , including forecasts for subscribers. This country databook contains high-level insights into UK peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account